AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28905478 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks, with potential increase to 150 mg every 2 weeks at week 12 if LDL cholesterol levels were ≥1.8 mmol/L at week 8.
Number of subjects: 517
Study 28905478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 517
Study 25783974 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with complete calcineurin inhibitor elimination
Number of subjects: 115
Study 25783974 — intervention group
Group type: COMPARATOR
Intervention: Standard cyclosporine immunosuppression
Number of subjects: 115
Study 23935818 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia software for teaching skin flap surgery
Number of subjects: 50
Study 23935818 — intervention group
Group type: COMPARATOR
Intervention: Standard text‐based print article
Number of subjects: 50
Study 20671295 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal d-amphetamine (0, 16, 24, and 32 mg/70 kg)
Number of subjects: 0
Study 20671295 — intervention group
Group type: COMPARATOR
Intervention: Oral d-amphetamine (equal doses to intranasal)
Number of subjects: 0
Study 19525742 — intervention group
Group type: EXPERIMENTAL
Intervention: Vietnam combat veterans with PTSD
Number of subjects: 124
Study 19525742 — intervention group
Group type: COMPARATOR
Intervention: Vietnam combat veterans without PTSD
Number of subjects: 124
Study 17954514 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine
Number of subjects: 300
Study 17954514 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol plus promethazine
Number of subjects: 300
Study 15311032 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 303
Study 15311032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 11490143 — intervention group
Group type: EXPERIMENTAL
Intervention: SLPI
Number of subjects: 45
Study 11490143 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysozyme
Number of subjects: 45
Study 11490143 — intervention group
Group type: COMPARATOR
Intervention: Lactoferrin
Number of subjects: 45
Study 11490143 — intervention group
Group type: COMPARATOR
Intervention: Total protein
Number of subjects: 45
Study 11490143 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and Gender
Number of subjects: 45
Study 10181019 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome information
Number of subjects: 0
Study 10181019 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancing information
Number of subjects: 0
Study 10181019 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sorts of information
Number of subjects: 0
Study 10181019 — intervention group
Group type: COMPARATOR
Intervention: No information
Number of subjects: 0
Study 10181019 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of outcome information and self-efficacy enhancing information
Number of subjects: 0
Study 7589026 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg controlled-release metoprolol
Number of subjects: 11
Study 2912356 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine-induced bronchospasm with theophylline
Number of subjects: 10
Study 2912356 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine-induced bronchospasm without theophylline
Number of subjects: 10
Study 2912356 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline-induced bronchospasm with theophylline
Number of subjects: 10
Study 2912356 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline-induced bronchospasm without theophylline
Number of subjects: 10
Study 2912356 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild bronchospasm
Number of subjects: 10
Study 1158628 — intervention group
Group type: EXPERIMENTAL
Intervention: Protriptyline
Number of subjects: 0
Study 1158628 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0
Study 31707832 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924
Study 31707832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study 31299610 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus treatment
Number of subjects: 121
Study 31299610 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 121
Study 28663046 — intervention group
Group type: EXPERIMENTAL
Intervention: Active VNS
Number of subjects: 96
Study 28663046 — intervention group
Group type: COMPARATOR
Intervention: Inactive VNS (Control)
Number of subjects: 96
Study 26032788 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided affective imagery
Number of subjects: 15
Study 23777744 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B (100 kV protocol at pitch 3.2 with a cardiac bowtie‐shaped filter)
Number of subjects: 100
Study 23777744 — intervention group
Group type: COMPARATOR
Intervention: Protocol A (standard 100 kV protocol at pitch 2.8)
Number of subjects: 100
Study 23777744 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B
Number of subjects: 100
Study 23777744 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative reconstruction
Number of subjects: 100
Study 21784729 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100 mg plus MTX
Number of subjects: 444
Study 21784729 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 50 mg plus MTX
Number of subjects: 444
Study 21784729 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100 mg plus placebo
Number of subjects: 444
Study 21784729 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 50 mg plus placebo
Number of subjects: 444
Study 21784729 — intervention group
Group type: COMPARATOR
Intervention: placebo plus MTX
Number of subjects: 444
Study 19525747 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 90
Study 19525747 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 90
Study 16944674 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of zolpidem (Z)
Number of subjects: 16
Study 16944674 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 16
Study 15351162 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil introduction with cyclosporine reduction (target trough levels 2-4 microg/ml)
Number of subjects: 161
Study 15351162 — intervention group
Group type: COMPARATOR
Intervention: Control group with unchanged immunosuppression
Number of subjects: 161
Study 11933416 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐adherent, hydroactive, polyurethane dressing alone
Number of subjects: 12
Study 11933416 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane plus compression
Number of subjects: 12
Study 11933416 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone sheeting plus compression
Number of subjects: 12
Study 11933416 — intervention group
Group type: COMPARATOR
Intervention: Compression alone
Number of subjects: 12
Study 9497765 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS-Empress full-porcelain crowns
Number of subjects: 34
Study 8441139 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 50 mg tid
Number of subjects: 27
Study 8441139 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 60 mg intramuscularly
Number of subjects: 27
Study 3911309 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal ultrasonography
Number of subjects: 181
Study 3911309 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 181
Study 30173873 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 323
Study 30173873 — intervention group
Group type: COMPARATOR
Intervention: Formula feeding
Number of subjects: 323
Study 30173873 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal diet during pregnancy
Number of subjects: 323
Study 30173873 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid food introduction
Number of subjects: 323
Study 30173873 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding and child race/ethnicity interaction
Number of subjects: 323
Study 27473180 — intervention group
Group type: EXPERIMENTAL
Intervention: Samvedana Plus intervention (multi-level intervention programme)
Number of subjects: 800
Study 27473180 — intervention group
Group type: COMPARATOR
Intervention: Control group (village clusters not receiving the intervention initially)
Number of subjects: 800
Study 24587570 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (400 mg)
Number of subjects: 27
Study 24587570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 21190800 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment (single implants on two occasions in summer, n=1399)
Number of subjects: 3901
Study 21190800 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment (n=1399)
Number of subjects: 3901
Study 21190800 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment in Herd A (n=1399)
Number of subjects: 3901
Study 21190800 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment at 60kg live-weight in Year 1
Number of subjects: 3901
Study 21190800 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated, n=2502)
Number of subjects: 3901
Study 21190800 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment in Herd B (n=1399)
Number of subjects: 3901
Study 19843776 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 75
Study 19843776 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 75
Study 18075942 — intervention group
Group type: EXPERIMENTAL
Intervention: VR + CM (Vocational Rehabilitation + Contingency Management)
Number of subjects: 100
Study 18075942 — intervention group
Group type: COMPARATOR
Intervention: VR only (Vocational Rehabilitation only)
Number of subjects: 100
Study 14754784 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous sertraline (50-100 mg/day)
Number of subjects: 0
Study 14754784 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent sertraline (50-100 mg/day)
Number of subjects: 0
Study 14754784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11553257 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg with metoclopramide 5 mg
Number of subjects: 120
Study 11553257 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 10 mg intravenously
Number of subjects: 120
Study 9631220 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic high resolution ultrasound technique for presence of posterior wall deficiency
Number of subjects: 35
Study 9631220 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic high resolution ultrasound technique
Number of subjects: 35
Study 9631220 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical, clinical, and ultrasound follow up for players who underwent hernia repair
Number of subjects: 35
Study 7946181 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine monotherapy (4.55 +/- 0.56 mg twice daily)
Number of subjects: 41
Study 7946181 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine plus bopindolol (7.5 +/- 0.63 mg twice daily and 1.16 +/- 0.12 mg once daily)
Number of subjects: 41
Study 7946181 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine monotherapy
Number of subjects: 41
Study 7946181 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine plus bopindolol
Number of subjects: 41
Study 7946181 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine monotherapy and Isradipine plus bopindolol
Number of subjects: 41
Study 3041824 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily evening doses of controlled-release theophylline (Uniphyl tablets)
Number of subjects: 300
Study 7433519 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin 30-80 mg daily
Number of subjects: 80
Study 7433519 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 15-40 mg daily
Number of subjects: 80
Study 30265333 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.2 mg)
Number of subjects: 150
Study 30265333 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 150
Study 28667408 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily administration of S-1 at a standard dose of 80 mg/m2/day
Number of subjects: 132
Study 28667408 — intervention group
Group type: COMPARATOR
Intervention: Alternate-day administration of S-1 on 4 days a week
Number of subjects: 132
Study 28667408 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily administration of S-1
Number of subjects: 132
Study 28667408 — intervention group
Group type: COMPARATOR
Intervention: Alternate-day administration of S-1
Number of subjects: 132
Study 26081934 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week exercise intervention (3 sessions/week)
Number of subjects: 150
Study 26081934 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control) group
Number of subjects: 150
Study 23108008 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete Revitalens MPDS
Number of subjects: 25
Study 23108008 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotrue MPDS
Number of subjects: 25
Study 20825804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous (IO) line placement by first responders wearing PPE
Number of subjects: 18
Study 20825804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous (IO) line placement by first receivers wearing PPE
Number of subjects: 18
Study 20825804 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of time to completion among PPE levels
Number of subjects: 18
Study 20825804 — intervention group
Group type: COMPARATOR
Intervention: Line placements
Number of subjects: 18
Study 19954052 — intervention group
Group type: COMPARATOR
Intervention: MELD score < or = 9
Number of subjects: 254
Study 19954052 — intervention group
Group type: EXPERIMENTAL
Intervention: MELD score 10-19
Number of subjects: 254
Study 19954052 — intervention group
Group type: EXPERIMENTAL
Intervention: MELD score 20-29
Number of subjects: 254
Study 19954052 — intervention group
Group type: EXPERIMENTAL
Intervention: MELD score > or = 30
Number of subjects: 254
Study 19954052 — intervention group
Group type: COMPARATOR
Intervention: MELD score < or = 19
Number of subjects: 254
Study 17508038 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroprotective drug
Number of subjects: 0
Study 17508038 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 15600246 — intervention group
Group type: EXPERIMENTAL
Intervention: Peru-15 (recombinant cholera vaccine)
Number of subjects: 0
Study 15600246 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase II trial
Number of subjects: 0
Study 15600246 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase III trial
Number of subjects: 0
Study 15600246 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase IIb and phase III challenge studies
Number of subjects: 0
Study 11380056 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-school intervention including establishment of a school-based adolescent health team and implementation of strategies based on student surveys.
Number of subjects: 26
Study 9582768 — intervention group
Group type: EXPERIMENTAL
Intervention: Information leaflet (Group A)
Number of subjects: 120
Study 9582768 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet and verbal explanation (Group B)
Number of subjects: 120
Study 9582768 — intervention group
Group type: COMPARATOR
Intervention: Verbal explanation only (Group C)
Number of subjects: 120
Study 8109763 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.15 mg/kg (maximum = 8 mg)
Number of subjects: 60
Study 8109763 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 60
Study 3396118 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin 8 g b.i.d.
Number of subjects: 38
Study 3396118 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin 2 g t.i.d.
Number of subjects: 38
Study 3396118 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin
Number of subjects: 38
Study 5781487 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (40 to 80 mg daily for 17 months)
Number of subjects: 0
Study 5781487 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (40 to 80 mg daily for 9 months)
Number of subjects: 0
Study 30650159 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) sign-reading assistant
Number of subjects: 0
Study 30650159 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AR assistance)
Number of subjects: 0
Study 29162078 — intervention group
Group type: EXPERIMENTAL
Intervention: ProPA program (physical activity oriented home rehabilitation program)
Number of subjects: 0
Study 29162078 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study 26391359 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 100U
Number of subjects: 1105
Study 26391359 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1105
Study 22804755 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg/day for 28 days
Number of subjects: 16
Study 22804755 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study 21709648 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified triple loop corrector (appliance therapy)
Number of subjects: 39
Study 21709648 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive reinforcement (reward therapy)
Number of subjects: 39
Study 21709648 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 18651343 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 37.5 mg b.i.d. for 7 days followed by 75 mg b.i.d. for another 7 days
Number of subjects: 12
Study 18651343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18651343 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 12
Study 17961403 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dosage of ICS (fluticasone) plus LABA (salmeterol) maintained for 18 months in group A
Number of subjects: 65
Study 17961403 — intervention group
Group type: COMPARATOR
Intervention: Tailored dosage or withdrawal of therapy according to clinical control in group B
Number of subjects: 65
Study 17961403 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-down or withdrawal according to PC(35) sGaw in group C
Number of subjects: 65
Study 17961403 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with ICS plus LABA
Number of subjects: 65
Study 17961403 — intervention group
Group type: COMPARATOR
Intervention: Adjustment of therapy based on clinical parameters in group B
Number of subjects: 65
Study 17961403 — intervention group
Group type: EXPERIMENTAL
Intervention: PC(35) sGaw monitoring in therapy adjustment
Number of subjects: 65
Study 15336593 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT group (n = 146) received a sequential combination of 2 mg estradiol valerate and 1 mg cyproterone acetate and calcium lactate, 500 mg/day (equal to 93 mg Ca2+) alone or in combination with vitamin D3, 100‐300 IU/day.
Number of subjects: 316
Study 15336593 — intervention group
Group type: COMPARATOR
Intervention: non-HRT group (n = 170) received calcium lactate, 500 mg alone or in combination with vitamin D3, 100‐300 IU/day.
Number of subjects: 316
Study 15336593 — intervention group
Group type: COMPARATOR
Intervention: non-HRT group (n = 170) with wild-type NPY polymorphism.
Number of subjects: 316
Study 15336593 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT group (n = 146) with Leu7/Pro7 genotype.
Number of subjects: 316
Study 12964222 — intervention group
Group type: EXPERIMENTAL
Intervention: Profiling bed with a pressure-reducing foam mattress
Number of subjects: 100
Study 12964222 — intervention group
Group type: COMPARATOR
Intervention: Flat-based bed with an appropriate pressure-redistributing mattress
Number of subjects: 100
Study 9621829 — intervention group
Group type: EXPERIMENTAL
Intervention: Successive recognition judgments
Number of subjects: 0
Study 9621829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ease judgments
Number of subjects: 0
Study 7624633 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcortical through the middle T2 gyrus
Number of subjects: 80
Study 7624633 — intervention group
Group type: EXPERIMENTAL
Intervention: Translyvian through the deep sylvian fissure
Number of subjects: 80
Study 7624633 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcortical subpial through the anterior T1 gyrus
Number of subjects: 80
Study 7624633 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcortical through the first temporal sulcus
Number of subjects: 80
Study 2455148 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine tablet
Number of subjects: 6
Study 2455148 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 X 10 mg nifedipine capsules
Number of subjects: 6
Study 31920097 — intervention group
Group type: EXPERIMENTAL
Intervention: semi-immersive virtual reality training (sVRT)
Number of subjects: 60
Study 31920097 — intervention group
Group type: COMPARATOR
Intervention: conventional cognitive training (Control Group)
Number of subjects: 60
Study 31787023 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear Periodized Training (LP)
Number of subjects: 39
Study 31787023 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Linear Periodized Training (NLP)
Number of subjects: 39
Study 31787023 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 39
Study 30340637 — intervention group
Group type: EXPERIMENTAL
Intervention: Video clinic appointments
Number of subjects: 180
Study 30340637 — intervention group
Group type: COMPARATOR
Intervention: Standard face-to-face appointments
Number of subjects: 180
Study 28739794 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD-5847 (500 mg once daily)
Number of subjects: 60
Study 28739794 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD-5847 (1,200 mg once daily)
Number of subjects: 60
Study 28739794 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD-5847 (500 mg twice daily)
Number of subjects: 60
Study 28739794 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD-5847 (800 mg twice daily)
Number of subjects: 60
Study 28739794 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD-5847
Number of subjects: 60